id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2021-E-0791-0006,FDA,FDA-2021-E-0791,Letter from FDA CDER to U. S. Patent and Trademark Office,Other,Letter(s),2025-01-17T05:00:00Z,2025,1,2025-01-17T05:00:00Z,,2025-01-17T15:02:51Z,,0,0,09000064868cb188
FDA-2021-E-0791-0005,FDA,FDA-2021-E-0791,Determination of Regulatory Review Period for Purposes of Patent Extension; VILTEPSO,Notice,Determinations,2023-12-08T05:00:00Z,2023,12,2023-12-08T05:00:00Z,2024-02-07T04:59:59Z,2023-12-08T14:24:16Z,2023-27013,0,0,09000064863165a3
FDA-2021-E-0791-0004,FDA,FDA-2021-E-0791,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2023-12-01T05:00:00Z,2023,12,2023-12-01T05:00:00Z,,2023-12-29T13:19:14Z,,0,0,09000064862d4783
FDA-2021-E-0791-0003,FDA,FDA-2021-E-0791,Letter to U S Patent and Trademark Office,Other,Letter(s),2022-08-24T04:00:00Z,2022,8,2022-08-24T04:00:00Z,,2022-08-24T14:50:49Z,,0,0,090000648526eb3b
FDA-2021-E-0791-0002,FDA,FDA-2021-E-0791,"Patent Term Extension Application for VILTEPSO® (viltolarsen) Patent No. 9,079,934",Other,Application,2021-07-27T04:00:00Z,2021,7,2021-07-27T04:00:00Z,,2021-07-27T15:10:56Z,,0,0,0900006484c10e36
FDA-2021-E-0791-0001,FDA,FDA-2021-E-0791,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2021-07-27T04:00:00Z,2021,7,2021-07-27T04:00:00Z,,2021-07-27T15:10:31Z,,0,0,0900006484c10bf7